WallStSmart

Illumina Inc (ILMN)vsThermo Fisher Scientific Inc (TMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 929% more annual revenue ($45.20B vs $4.39B). ILMN leads profitability with a 19.4% profit margin vs 15.1%. TMO appears more attractively valued with a PEG of 1.62. TMO earns a higher WallStSmart Score of 62/100 (C+).

ILMN

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 8.5Value: 6.0Quality: 6.5
Piotroski: 6/9Altman Z: 1.72

TMO

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 4.0Quality: 6.0
Piotroski: 3/9Altman Z: 2.13
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ILMNUndervalued (+58.0%)

Margin of Safety

+58.0%

Fair Value

$276.80

Current Price

$162.32

$114.48 discount

UndervaluedFair: $276.80Overvalued
TMOSignificantly Overvalued (-41.7%)

Margin of Safety

-41.7%

Fair Value

$331.35

Current Price

$472.80

$141.45 premium

UndervaluedFair: $331.35Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ILMN1 strengths · Avg: 10.0/10
Return on EquityProfitability
31.9%10/10

Every $100 of equity generates 32 in profit

TMO1 strengths · Avg: 9.0/10
Market CapQuality
$179.15B9/10

Large-cap with strong market position

Areas to Watch

ILMN4 concerns · Avg: 4.0/10
P/E RatioValuation
29.2x4/10

Moderate valuation

Price/BookValuation
9.2x4/10

Trading at 9.2x book value

Revenue GrowthGrowth
4.8%4/10

4.8% revenue growth

Altman Z-ScoreHealth
1.724/10

Distress zone — elevated risk

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.624/10

Expensive relative to growth rate

P/E RatioValuation
26.5x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ILMN

The strongest argument for ILMN centers on Return on Equity. Profitability is solid with margins at 19.4% and operating margin at 18.3%.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap. Profitability is solid with margins at 15.1% and operating margin at 17.9%.

Bear Case : ILMN

The primary concerns for ILMN are P/E Ratio, Price/Book, Revenue Growth.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

ILMN profiles as a value stock while TMO is a mature play — different risk/reward profiles.

ILMN carries more volatility with a beta of 1.49 — expect wider price swings.

TMO is growing revenue faster at 6.2% — sustainability is the question.

TMO generates stronger free cash flow (816M), providing more financial flexibility.

Bottom Line

TMO scores higher overall (62/100 vs 56/100), backed by strong 15.1% margins. ILMN offers better value entry with a 58.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Illumina Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Illumina, Inc. is an American company. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in San Diego, California.

Visit Website →

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?